Asset Details
Do you wish to reserve the book?
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Do you wish to request the book?
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
2013
Overview
In a prospective, randomized, phase 3 trial of crizotinib as second-line therapy in patients who had disease progression while receiving a platinum-based regimen, crizotinib resulted in longer progression-free survival than did chemotherapy with pemetrexed or docetaxel.
Anaplastic lymphoma kinase (ALK) is a validated tyrosine kinase target in several cancers, including non–small-cell lung cancer, anaplastic large-cell lymphoma, and pediatric neuroblastoma.
1
–
3
ALK
rearrangements are found in approximately 5% of cases of non–small-cell lung cancer and define a distinct molecular subtype of lung cancer.
4
–
7
With an estimated 1.3 million new cases of non–small-cell lung cancer worldwide each year,
8
this translates into more than 60,000 patients with
ALK
-positive non–small-cell lung cancer annually.
Crizotinib is an oral small-molecule tyrosine kinase inhibitor targeting ALK, MET, and ROS1 tyrosine kinases.
1
,
9
,
10
In two single-group studies, crizotinib showed marked antitumor . . .
Publisher
Massachusetts Medical Society
Subject
/ Aged
/ Alopecia
/ Antineoplastic Agents - adverse effects
/ Antineoplastic Agents - therapeutic use
/ Biological and medical sciences
/ Carcinoma, Non-Small-Cell Lung - drug therapy
/ Carcinoma, Non-Small-Cell Lung - mortality
/ Dyspnea
/ Fatigue
/ Female
/ Glutamates - adverse effects
/ Glutamates - therapeutic use
/ Guanine - analogs & derivatives
/ Humans
/ Liver
/ Lung Neoplasms - drug therapy
/ Lymphoma
/ Male
/ Multiple tumors. Solid tumors. Tumors in childhood (general aspects)
/ Patients
/ Platinum
/ Protein Kinase Inhibitors - adverse effects
/ Protein Kinase Inhibitors - therapeutic use
/ Tumors
